Stimulating progress

Company

At Neuromod, we are committed to stimulating progress through the design, clinical validation and commercialisation of neuromodulation technologies.

Neuromod was founded in 2010, to develop and commercialise a treatment for chronic tinnitus. We are an ISO 13485 accredited medical device manufacturer based in Dublin, Ireland and are supported by a network of long-established and internationally recognised partners.

Stimulating leadership

Leadership

Our management and board share a commitment towards achieving significant breakthroughs in the field of bi-modal neuromodulation. Together, we bring our collective skills, talents and experience to bear on the pursuit of this ambitious endeavour.

Our team includes ear, nose and throat (ENT) surgeons, neuroscientists, audiologists, clinicians, engineers, regulatory experts, product designers and others who are instrumental to our vision of realising the untapped potential of neuromodulation in medicine.

Team Management

Dr. Ross O’Neill PhD MBA

Founder & CEO Linkedin

Mr. Brendan Conlon ENT

Chief Medical Officer Linkedin

Dr. Hubert Lim PhD

Chief Scientific Officer Linkedin

Stephen Hughes BEng

Chief Technology Officer Linkedin

Rosemarie Tully BSc (Pharm), MBA, MPSI

Chief Business Officer Linkedin

Derek Madden CPA CTax

Chief Financial Officer Linkedin

Caroline Hamilton BSc (Aud) MSc (Neuro)

Clinical Director Linkedin

Board of Directors

Dr. Ross O’Neill PhD MBA

Director Linkedin

Ross is a biomedical engineer with a personal passion for developing neuromodulation therapies for hearing and auditory system disorders. He founded Neuromod in 2010 to develop non-invasive neuromodulation treatments for chronic neurological disorders.

Dr. Manus Rogan PhD MBA

Chairman Linkedin

Manus is a chemist who began his career in drug development before moving into business development and venture capital investment, establishing Fountain Healthcare Partners in the 2000’s to invest in groundbreaking technologies in the life science sector.

Mr. Christopher Smith

Non-Executive Director Linkedin

Mr. Smith comes to Neuromod’s board with an exemplary track record of leadership in the hearing and medical devices sectors. In January 2018, after 14 years with the company, Mr. Smith retired from his role as Chief Executive Officer and Director of Cochlear Ltd (COH.ASX), the global leader in cochlear implantation technology. During his time at the helm of Cochlear, Mr. Smith oversaw a period of substantial growth reaching annual sales in excess of AUD 1 billion dollars and the market cap of the company grow to AUD 10 billion (USD 7.5 billion).

Partnership

We are proud to be working with a number of partners who share and respect our vision of this game-changing therapeutic breakthrough.

  • Investment Partners
    • Fountain Healthcare
    • Enterprise Ireland
  • Regulatory and Biostatistical Advisors
    • NAMSA
  • Notified Body
    • BSI
  • Legal Partners
    • Byrne Wallace
  • Audit and Advisory Partners
    • KPMG
  • European Patent Attorneys
    • Tomkins
  • US Patent Attorneys
    • Shay Glenn LLP